|
A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF. Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF. conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF. Clinical research trials and A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF. healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF.. A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF. Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF. clinical trial. Test subjects oftentimes recieve the best healthcare possible for their A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF. condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF.  A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF.
A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF.
For Condition: Renal Cell Carcinoma
Status: Recruiting
Sponsor(s): Abgenix , Immunex Corporation
Synopsis: Part 1: To determine the safety and effectiveness of up to 4 different doses of ABX-EGF in patients with renal cancer. Part 1: Closed, no longer recruiting (Completed December 2003) Part 2: To determine the safety and effectiveness of a defined dose of ABX-EGF in renal cancer patients, who had nephrectomy and either failed one biotherapy or received no prior therapy. (Currently Recruiting)
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Diagnosis of renal cell carcinoma - Previously failed one biotherapy or no prior therapy - Has bi-dimensionally measurable disease - Has tumor tissue available for diagnostics - Normal renal and liver functions Exclusion Criteria: - Brain metastases - Hypercalcemia (unless treated) - Cancer therapy within 30 days of study drug infusion - Use of any investigational drug within 30 days of study drug infusion. - Prior treatment with another anti-EGFr agent - Left ventricular ejection fraction <45% - Myocardial infarction within one year prior to entering the study - Other active cancer and required treatment within the past 5 years excluding prior renal cell, basal cell or cervical - Pregnant or breast feeding - Male or female of child bearing potential unwilling to use birth control - Known HIV + - History of chronic medical or psychiatric condition that my interfere with the interpretation of the study results
Total Enrollment: 115
Location and Contact Information:
Our Lady of Mercy Medical Center Comprehensive Cancer Center *Recruiting*
Bronx, New York, 10466
United States
Recruiting Linda Sacres 718-920-9057
UCLA School of Medicine *Recruiting*
Los Angeles, California, 90095
United States
Recruiting Nancy Moldawer 310-206-6966
Fox Chase Cancer Center *Recruiting*
Philadelphia, Pennsylvania, 19111
United States
Recruiting Naomi Haas 215-728-2974
University of Nebraska Medical Center *Recruiting*
Omaha, Nebraska, 68198-7680
United States
Recruiting Rose Solberg 402-559-8649
Beth Israel Deaconess Medical Center *Recruiting*
Boston, Massachusetts, 02215
United States
Recruiting Maria Guerrieri 617-667-1904
The Institute for Drug Development Cancer Therapy and Research Center *Recruiting*
San Antonio, Texas, 78229
United States
Recruiting Stephanie Hodges 210-616-5798
Cleveland Clinic Cancer Center *Recruiting*
Cleveland, Ohio, 44195
United States
Recruiting Ronald Bukowski 216-444-6825
Additional Information:
Study ID Numbers: ABX-0303; 054-0003
Study Start Date: February 2003
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00036530
Other Renal Cell Carcinoma Studies:
1. Vaccine Therapy with Tumor Specific Mutated VHL Peptides in Adult Cancer Patients with Renal Cell Carcinoma
2. A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF.
3. A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer
4. Survival Study Of Oncophage® vs. Observation In Patients with Kidney Cancer
5. Stem Cell Transplant for Advanced Renal Cell Cancer
Related Studies:
Other Renal Cell Carcinoma Clinical Trials
Other Nebraska Clinical Trials
Other Omaha Clinical Trials
A research study in patients with renal cancer to determine the safety and effectiveness of a new investigational drug called ABX-EGF.
|
|
|
|
|
|
|
|
